Open Orphan, a European-focussed, rare and orphan drug consulting services platform, informed investors of the deal.

Dublin-listed pharma services company Open Orphan has signed a new three-year contract with a German pharmaceutical company, which it said will guaran(...)

Integumen offers a range of products in the skin science, oral health and woundcare sector. Photograph: iStock

Dalkey-based Integumen is to raise £1.4 million (€1.66 million) through a share placing and subscription to provide working capital as it looks to boo(...)

Open Orphan is the result of Cathal  Friel reversing his pharma services business of the same name into Dublin-listed drug clinical trials manager Venn Life Sciences earlier this year

Dublin-listed pharma services company Open Orphan said on Monday it has agreed to merge with UK-based Hvivo in a £30 million (€35.7m) tie-up that clas(...)

Photograph: iStock

Open Orphan, the pharma services business which completed a reverse takeover into clinical trials group Venn Life Sciences earlier this year, made a €(...)

Pharma services business Open Orphan said admission and dealings in its ordinary shares of 0.1 pence each on AIM and Euronext Growth Dublin would commence at 8am on Friday under the ticker ORPH

Pharma services business Open Orphan, formerly known as Venn Life Sciences, has resumed trading on the stock exchanges in Dublin and London following (...)

Venn Life Sciences unveiled full-year results for 2018 on Tuesday, which showed the company’s sales dropped to €14.3 million from €17.8 million for the previous year.

Dublin-listed drug clinical trials manager Venn Life Sciences, which is in the process of merging with dealmaker Cathal Friel’s pharma services busine(...)

Cathal Friel, who has taken over as chief executive at Venn Life Sciences following an agreement to merge it with his company, Open Orphan. Photograph: Fennell Photography

Leading corporate figure Cathal Friel is behind the proposed reverse takeover of listed clinical trials group Venn Life Sciences by pharma services bu(...)

Theratechnologies aims to improve the quality of life for HIV patients. Photograph: iStock

A Canadian speciality pharmaceutical company has appointed Dublin man Conor Walshe as general manager of its European subsidiary. Theratechnologies,(...)

Venn Life Sciences chief executive Tony Richardson. Venn has established full-service clinical research programmes and activities in 27 different countries

Clinical trials group Venn Life Sciences has signed a strategic collaboration with Open Orphan DAC as it seeks to increase its focus on rare diseases (...)

IPHA president GSK’s Aidan Lynch (centre); IPHA vice-president Paul Reid (Pfizer); and Bayer’s Itziar Canamasas with the Manifesto for Better Health ahead of the IPHA annual conference on November 8th. Photograph: Justin Mac Innes

Big Pharma in Ireland has an image problem. At least that’s how it sees it. “I think we are not seen as a trusted partner,” says Aidan Lynch, presid(...)

  • 1
  • 2
  • 3
  • 4
  • Next
  • Last »